Prostate Cancer Coverage from Every Angle

Christopher Sweeney, MBBS, on Adding Enzalutamide to the Treatment Landscape for Metastatic Hormone-Sensitive Prostate Cancer

Posted: Sunday, June 2, 2019

Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, discusses how he sees enzalutamide fitting into the treatment landscape for testosterone suppression in metastatic hormone-sensitive prostate cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.